The anti-CD30 antibody-drug conjugate brentuximab vedotin, which has shown benefit in patients with relapsed or refractory HL [12, 13], has been approved in the United States and Europe for the treatment of HL after failure of AHSCT or after failure of two or more previous multiagent chemotherapy regimens in patients who are not candidates for AHSCT [3]. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.